Form 4: Teva Pharmaceutical Industries CFO Eliyahu Sharon Kalif Reports Share Sale and Option Exercise
SEC Form 4
EVP and CFO of Teva Pharmaceutical Industries, Eliyahu Sharon Kalif, reports the sale of 55,750 ordinary shares and the exercise of options for 49,800 shares.
Summary
- Eliyahu Sharon Kalif, the EVP and CFO of Teva Pharmaceutical Industries, filed a Form 4 detailing changes in beneficial ownership.
- On February 28, 2025, Kalif sold 55,750 ordinary shares at a weighted average price of $16.2056 per share.
- The sale was executed under a Rule 10b5-1 trading plan adopted on November 29, 2024.
- On March 3, 2025, Kalif exercised options for 49,800 ordinary shares.
- Following these transactions, Kalif directly owns 197,741 ordinary shares and 99,602 restricted share units.
- The restricted share units were granted on March 3, 2023, and vest in installments through March 3, 2027.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing transactions by a company executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates the CFO's transactions in Teva shares.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company executives as it can provide insights into management's perspective on the company's value.
Key Dates
| Date | Description |
|---|---|
| March 3, 2023 | Restricted share units were granted. |
| November 29, 2024 | Rule 10b5-1 trading plan adopted. |
| February 28, 2025 | Sale of 55,750 ordinary shares. |
| March 3, 2025 | Exercise of options for 49,800 ordinary shares; vesting of 49,800 restricted share units. |
| March 3, 2026 | 49,800 restricted share units vesting. |
| March 3, 2027 | 49,802 restricted share units vesting. |
| March 4, 2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.